AUTHORS
Bo Zhang, Honglan Wang2, Xinyue Deng, MD3, Zhihao Xing4, Heng Mei5, Tao Guo6, Minghua Yang7, Zhiqing Pang8, Hu Yu, MD9
AFFILIATIONS
1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
3 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
4 Shenzhen Children's Hospital, Shenzhen Pediatrics Institute of Shantou University Medical College, Shenzhen, Guangdong, China
5 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
6 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
7 Third Xiangya Hospital, Central South University, Changsha, Hunan, China
8 School of Pharmacy, Fudan University, Shanghai, China
9 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
ABSTRACT
OBJECTIVE: Hemophagocytic lymphohistiocytosis (HLH) is a lethal hyperinflammatory syndrome characterized by pathological immune activation and cytokine storm. To address the critical need for targeted therapies, single-cell transcriptomic profiling was integrated to dissect disease drivers and identify therapeutic vulnerabilities, followed by the rational design of a biomimetic liposomal delivery system to facilitate clinical translation.
METHODS: Single-cell RNA sequencing was performed on peripheral blood samples from patients with HLH to identify dysregulated immune cell populations and signaling pathways. Candidate therapeutic targeting agents were selected based on aberrantly enriched pathways and subsequently evaluated in murine HLH models. Following identification of the most effective candidate, a novel liposomal delivery system was developed to further improve therapeutic efficacy and biosafety.
RESULTS:
Identification of candidate therapeutic agents by single-cell transcriptomic analysis: Peripheral blood samples from 17 pediatric patients with HLH and 3 healthy volunteers were subjected to single-cell RNA sequencing. Monocytes were markedly expanded in patients with HLH compared with healthy controls. Based on the enriched dysregulated signaling pathways in monocytes, several candidate therapeutic agents, including decitabine (DAC), were selected for further tests.
Validation of therapeutic efficacy in murine HLH models: The candidate agents were evaluated in two murine HLH models induced by CpG and LPS/poly(I:C), respectively. Among all tested agents, DAC demonstrated the most potent therapeutic efficacy in both models, in which DAC significantly ameliorated cardinal manifestations of HLH, including hypercytokinemia, abnormal hepatorenal function and organomegaly, ultimately rescuing the mice from lethal HLH with 100% survival.
Development and evaluation of a novel DAC liposomal delivery system: A reactive oxygen species (ROS)-responsive and macrophage membrane-fused liposomal prodrug formulation of DAC (M-Lipo-DAC) was then developed. In vitro experiments demonstrated that M-Lipo-DAC exhibited effective adsorption of crucial cytokines such as IFN-γ and IL-6 and ROS-responsive release of DAC. In vivo, M-Lipo-DAC achieved superior therapeutic efficacy compared with free DAC or macrophage membrane-fused empty liposomes without DAC (M-Lipo). Furthermore, no obvious treatment-related toxicity was observed in either healthy mice or murine HLH models.
CONCLUSIONS: As DAC and drug-loaded liposomes are already in widespread clinical use and macrophage membranes possess favorable biocompatibility, both repurposed DAC and the M-Lipo-DAC platform developed here hold promising clinical translational value for HLH and, potentially, other cytokine-storm–related disorders.
DISCLOSURES
Bo Zhang: No relevant conflicts of interest to declare.